Terminated PHASE3 INTERVENTIONAL 2-arm NCT00148616

Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia

Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Chronic Schizophrenia: Results of a Proof of Concept Study

Sponsor: M. Schaefer, MD

Conditions Chronic Schizophrenia

Interventions Memantine Placebos

Updated 6 times since 2017 Last updated: Jun 25, 2019 Started: Apr 30, 2004 Primary completion: Jun 30, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from M. Schaefer, MD

Schizophrenia · Phase PHASE3 · Dec 2008

More terminations from M. Schaefer, MD

Listed as NCT00148616, this PHASE3 trial focuses on Chronic Schizophrenia and remains terminated or withdrawn. Sponsored by M. Schaefer, MD, it has been updated 6 times since 2004, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jul 2019 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — Jul 2019 [monthly]

Terminated PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE3

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M. Schaefer, MD
Stanley Medical Research Institute

Data source: Charite University, Berlin, Germany

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany